CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update.
To access the conference call:
The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.
In addition to the conference call, management will participate in the following upcoming investor conferences:
To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a clinical stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
| Last Trade: | US$1.33 |
| Daily Change: | -0.19 -12.50 |
| Daily Volume: | 3,027,579 |
| Market Cap: | US$109.790M |
October 21, 2024 October 03, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
